Capital Flow Monitor · Sponsors · CIK 2018060
270 Healthcare Growth Fund I LP
390 Madison Avenue, New York, NY, 10017 · 212-464-1649
Pooled Investment Fund / Private Equity Fund · Limited Partnership· inc. DELAWARE true 2024
Fit score
—
Offering
—
Sold
$113.9M
% sold
—
Investors
27
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-09-29 | D/A ·current | 506(b) | — | $113.9M | — | 27 | EDGAR ↗ |
| 2025-09-29 | D | 506(b) | — | $0 | — | 0 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- N/A 270 Healthcare Growth Fund I GP LLC — Director, New York, NY
-
Gaurav Gupta — Executive Officer, New York, NY
6 other raises
- 270 Healthcare Growth Fund I (LUX) SCSp-RAIF $113.9M of —
- 270 Life Sciences Private Capital Fund II (US) LP $0 of —
- 270 Life Sciences Private Capital Fund II (Cayman) LP $0 of —
- Raintank Inc. $250.0M of $250.0M · 100.0%
- Floating Capital Onshore Fund LP $10.8M of —
- Floating Capital Offshore Fund LP $0 of —
-
Anya Schiess — Executive Officer, New York, NY
1 other raise
- 270 Healthcare Growth Fund I (LUX) SCSp-RAIF $113.9M of —
-
Patrick McGoldrick — Executive Officer, New York, NY
5 other raises
-
Samantha Beattie — Executive Officer, New York, NY
13 other raises
- 270 Healthcare Growth Fund I (LUX) SCSp-RAIF $113.9M of —
- 270 Life Sciences Private Capital Fund II (US) LP $0 of —
- 270 Life Sciences Private Capital Fund II (Cayman) LP $0 of —
- 270 Hybrid Growth Onshore Fund, LP $0 of —
- 270 Hybrid Growth Cayman Fund, LP $0 of —
- 270 Private Capital Opportunities Fund IV, LP $124.0M of —
- 270 Private Capital Fund III, LP $0 of —
- 270 Private Capital Fund III (Offshore), LP $0 of —
- 270 Private Capital Opportunities Fund II, LP $0 of —
- 270 Private Capital Opportunities Fund I, LP $1.52B of —
- 270 Private Capital Opportunities Fund I (Offshore), LP $177.4M of —
- 270 Growth Partners IV SPV, LP $391.8M of —
- 270 Growth Partners III SPV, LP $25.0M of $25.0M · 100.0%
-
Stephen Squinto — Executive Officer, New York, NY
5 other raises
- 270 Healthcare Growth Fund I (LUX) SCSp-RAIF $113.9M of —
- 270 Life Sciences Private Capital Fund II (US) LP $0 of —
- 270 Life Sciences Private Capital Fund II (Cayman) LP $0 of —
- Averna Therapeutics Inc. $85.0M of $85.0M · 100.0%
- Enlaza Therapeutics, Inc. $15.0M of $15.0M · 100.0%
-
Joseph Siletto — Executive Officer, New York, NY
2 other raises
- 270 Healthcare Growth Fund I (LUX) SCSp-RAIF $113.9M of —
- ABK Biomedical Inc $2.6M of $2.6M · 100.0%
Placement agents
- J.p. Morgan Securities Llc · 17 RE raises
- J.p. Morgan Institutional Investments Inc. · 1 RE raises
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.